期刊文献+

2001~2009年泰安市急性弛缓性麻痹病例监测分析 被引量:3

Analysis on Surveillance of AFP Cases in Tai'an City,2001-2009
原文传递
导出
摘要 [目的]评价泰安市无脊灰后急性弛缓性麻痹(AFP)病例监测工作质量,为其他传染病控制提供借鉴。[方法]对2001-2009年泰安市AFP病例监测资料进行分析。[结果]2001-2009年泰安市累积报告AFP病例198例,15岁以下人群年均报告发病率为2.55/10万。6县(市、区)15岁以下人群年均报告发病率,宁阳县为5.85/10万,泰山区为1.25/10万,岱岳区为1.65/10万,肥城市为2.35/10万,新泰市为2.03/10万,东平县为2.37/10万(P〈0.01)。198例AFP病例中,〈1-4岁的分别占11.62%、13.64%、12.63%、8.59%,5-9岁占26.26%,10-15岁占19.19%;男性占65.66%,女性占34.34%;报告时间5-10月的占66.67%;乡镇级医疗单位报告的占1.01%,县级医院报告的占32.83%,地(市)级医院报告的占50.00%,省级医院报告的占14.14%,主动搜索发现的占2.02%;及时报告率为97.98%,及时调查率为100.00%,及时随访率为98.48%。检测191例双份粪便标本,分离出32株肠道病毒,包括非脊灰肠道病毒19株,I-Ⅲ型脊灰疫苗株分别为4、3、6株,未检出脊灰野病毒。[结论]2001-2009年泰安市AFP病例各项监测指标均在较高水平,未发现脊灰野病毒引起的病例。 [Objective]To evaluate the quality of post-poliomyelitis AFP surveillance program,so as to provide reference for other disease control.[Methods]Analysis was made on AFP monitoring data in 2001-2009.[Results]In 2001-2009,there were 198 AFP cases reported in Tai'an,and the average annual reported incidence of people less than 15 years old was 2.55/105 The average annual reported incidence in 6 counties(cities,districts) was 5.85/105 in Ningyang,1.25/105 in Taishan district,1.65/105 in Daiyue district,2.35/105 in Feicheng city,2.03/105 in Xintai city,and 2.37/105 in Dongping county(P0.01),in 198 AFP patients,cases aged 1 accounted for 8.08%,cases aged 1,2,3,and 4 accounted for 11.62%,13.64%,12.63%,and 8.59% respectively,cases aged 5-9 accounted for 26.26%,10-15 accounted for 19.19%;and males accounted for 65.66% and females accounted for 34.34%;there was 66.67% reported in May-October;and 1.01% was reported by town-level medical units,50.00% was reported by city-level medical units,14.14% was reported by provincial-level medical units,2.02% was found by initiative searching,and the ratio of timely reporting was 97.96%,the ratio of timely investigation was 100.00%,and the ratio of timely follow-up was 98.48%.191 double-feces samples were tested,and 32 strains of enterovirus,including 19 strains of non-polio enterovirus,4 type I polio-vaccine strains,3 type Ⅱ,6 type Ⅲ and none wild poliovirus.[Conclusion]In 2001-2009,all AFP cases are at a higher level in monitoring indicators in Tai'an City,and f no cases of polio caused by wild virus have been found.
作者 谢学迎
出处 《预防医学论坛》 2011年第4期341-343,共3页 Preventive Medicine Tribune
关键词 免疫规划 脊髓灰质炎 急性弛缓性麻痹病例 监测 EPI Poliomyelitis AFP Monitoring
  • 相关文献

参考文献5

二级参考文献23

  • 1痔临床诊治指南(2006版)[J].中华胃肠外科杂志,2006,9(5):461-463. 被引量:2138
  • 2Li J, Zhang LB, Yoneyama T, et al. Genetic basis of the neuroviru-lence of type 1 polioviruses isolated from vaccine-associated paralytic patients. Arch Virol, 1996, 141:1047-1054
  • 3Dowdle WR, De Gourville E, Kew OM, et al. Polio eradication: the OPV paradox. Rev Med Virol, 2003, 13:277-291
  • 4Kew 0M, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ,2004, 82:16-23
  • 5Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived poliovimses, January 2003-June 2004. MMWR, 2004, 53:990-993
  • 6Sutter RW, Caceres VM, Mas L,et al. The role of routine polio immunization in the post-certification era. Bull World Health Organ, 2004,82 : 31-39
  • 7Yang CF, Naguib T, Yang SJ,et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol,2003, 77 : 8366-8377
  • 8Kew OM, Glasgow VM, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science, 2002, 296 : 356-359
  • 9Centers for Disease Control and Prevention. Acute flaccid paralysis associated with circulating vaccine-derived poliovirus -Philippines,2001. JAMA, 2002, 287:311
  • 10Rousset D, Andrianarivelo MR, Razatindratsimandresy R, et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis, 2003, 9 : 885-887

共引文献45

同被引文献25

  • 1王佳庄,辉李杰.脊髓灰质炎疫苗衍生病毒的感染及预防[J].传染病信息,2005,18(2):58-60. 被引量:5
  • 2WHO. Infected countries [ EB/OL ]. http://www, polioeradication, org/ Infectedcountries. aspx. 2011,12[2012 - 07 - 15].
  • 3WHO. Vaccines and biologicals: report of the interim meeting of the technical consultative group(TCG)on the global eradication of poliomy- elitis, Geneva, November 9 - 11,2002 [ C]. Geneva, World Health Orga- nization, 2003.
  • 4WHO. Progress towards global poliomyelitis eradication, preparation for the oral poliovirus vaccine cessation era[J]. WER,2004,79(39) :349- 355.
  • 5WHO. Laboratory surveillance for wild and vaccine- derived poliovir- uses, January 2007 - June 2008 [ J ]. WER, 2008,83 ( 36 ) : 321 - 328.
  • 6GPEI. OPV cessation - time to proceed by individual serotypes[J ]. Polio Pipeline, 2011,8:3 - 4.
  • 7Collette MS,Neyts J,Modlin JF. A case for developing antiviral drugs against polio[J].Antiviral Research,2008,(03):179-187.doi:10.1016/j.antiviral.2008.04.002.
  • 8WHO. Resurgence of wild poliovirus types 1 and 3 in 15 African countries,January 2000-March 2009[J].WER,2009,(16):133-140.
  • 9刘方,贾滨,王珊.北京市朝阳区异地急性弛缓性麻痹病例流行病学分析[J].预防医学情报杂志,2009,25(8):644-645. 被引量:2
  • 10张振国,陈玫,郭玉,张俊棉,李静,赵娜,崔志强.2007-2008年河北省急性迟缓性麻痹病例脊灰病毒核苷酸变异情况分析[J].预防医学情报杂志,2009,25(12):1020-1022. 被引量:7

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部